|
Archived News |
NYBA News |
Press Release
|
| |
|
|
Progenics Pharmaceuticals, Inc. |
|
Headline:
Progenics Phase 1 PSMA ADC Study Presented in New "Trials in Progress" Poster Session at ASCO Annual Meeting
Date:
07-Jun-2010
News Type:
Member News
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing dose ...
Details »
|
|
| |
|
Progenics Pharmaceuticals, Inc. |
|
Headline:
Progenics Presents Novel Monoclonal Antibodies against Clostridium difficile at the American Society for Microbiology Conference
Date:
27-May-2010
News Type:
Member News
-- Antitoxin antibodies demonstrated positive activity in laboratory and animal models of C. difficile-associated disease --
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neu ...
Details »
|
|
| |
|
Genentech Inc. |
|
Headline:
Phase III Study Showed First-Line Maintenance Use of Rituxan(R) Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening
Date:
20-May-2010
News Type:
Member News
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today announced data from the Phase III PRIMA study. The data showed that continuing Rituxan® (rituximab) for two years in patients who responded to initial treatment with Rituxan plus chemotherapy, doubled the likelihood of them living without their disease worsening ...
Details »
|
|
| |
|
Acorda Therapeutics, Inc |
|
Headline:
Acorda Therapeutics Recognized by National Organization for Rare Disorders for Contribution to Treatment of Multiple Sclerosis
Date:
18-May-2010
News Type:
Member News
Acorda Received FDA Approval in January 2010 for AMPYRA(TM), A New Treatment for People with Multiple Sclerosis
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases. Earlier this year, Acorda received approval from the U.S. Food and Drug A ...
Details »
|
|
| |
|
Alzheimers Drug Discovery Foundation |
|
Headline:
AWARDS FOR BIOMARKER DISCOVERY RESEARCH FOR Lewy Body Dementia ANNOUNCED
Date:
17-May-2010
News Type:
Member News
The Alzheimer's Drug Discovery Foundation (ADDF) and the Lewy Body Dementia Association (LBDA) announced today the recipient of their first partnership research award through the Lewy Body Dementia Biomarker Research Program.The goal of the program is to catalyze the discovery of innovative biomarkers that aid in early diagnosis, detection and disease monitoring of Lewy body dementias (LBD ...
Details »
|
|
| |
|
OSI Pharmaceuticals Inc. |
|
Headline:
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Date:
16-May-2010
News Type:
Member News
--Companies enter into definitive merger agreement to combine to create a world-class oncology platform --OSI Stockholders to receive $57.50 per share in cash
Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of ...
Details »
|
|
| |
|
Amgen, Inc. |
|
Headline:
Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients
Date:
14-May-2010
News Type:
Member News
Submission Includes Data from Three Pivotal Phase 3 Trials
Amgen Inc. (Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including appro ...
Details »
|
|
| |
|
Regeneron Pharmaceuticals, Inc. |
|
Headline:
Regeneron Provides Initial Data on Two Antibody Product Candidates
Date:
12-May-2010
News Type:
Member News
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize full ...
Details »
|
|
| |
|
SUNY at Stony Brook |
|
Headline:
SBU RECEIVES FOURTH CONSECUTIVE SCIENCE EDUCATION GRANT FROM OSI PHARMACEUTICALS FOUNDATION
Date:
12-May-2010
News Type:
Member News
OSI Pharmaceuticals Foundation has awarded a grant to the High School Protein Modeling Challenge. The Challenge is centered on teams of high school students that use information from scientific databases and current research literature to build a model of a protein. The models are assessed by teams of judges from OSI and the University. For the past three years the program ...
Details »
|
|
| |
|
Alzheimers Drug Discovery Foundation |
|
Headline:
ALZHEIMER’S DRUG DISCOVERY FOUNDATION FUNDS AMICUS THERAPEUTICS TO ADVANCE PHARMACOLOGICAL CHAPERONE TECHNOLOGY
Date:
10-May-2010
News Type:
Member News
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (NASDAQ: FOLD; Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer’s disease.
Amicus has discovered an apparent link between various lysosomal enzymes and accu ...
Details »
|
|
| |
|
|
